TNFRSF17 and plasma cell myeloma: In clinical studies, BCMA (B-cell maturation antigen) is the most popular target antigen for multiple myeloma, and the basis of the antiBCMA-CAR-NK cell’s antigen recognition domain is the sequence of a monoclonal antibody that targets BCMA.